RxDoctor Payments Data

Marina Turner

Family · Nags Head, NCNPI 1679096945

Payments from drug & device makers

$1,634in general payments, 2019–2025

Across 98 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$620
  • Novo Nordisk$202
  • Teva Pharmaceuticals USA, Inc.$120
  • Actelion Pharmaceuticals US, Inc.$108
  • Novartis$106
  • Dexcom, Inc.$96
  • plus $382 from 11 others

What the payments were for

  • Food & beverage$1,634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,634 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$105,544
Medicare patients
341
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$128,554
JardianceEmpagliflozin105$107,871
EliquisApixaban59$60,255
JanuviaSitagliptin Phosphate42$49,170
XareltoRivaroxaban33$32,930
FarxigaDapagliflozin Propanediol16$27,029
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$24,609
EntrestoSacubitril/Valsartan21$24,340
Nurtec OdtRimegepant Sulfate12$24,250
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$15,564
RybelsusSemaglutide14$13,115
Tresiba Flextouch U-100Insulin Degludec15$6,543
SymbicortBudesonide/Formoterol Fumarate14$3,672
Atorvastatin Calcium362$3,618
Levothyroxine Sodium305$3,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$202$141,67089 claims
Boehringer IngelheimJardiance$74$107,871105 claims
PfizerEliquis, Nurtec Odt$30$84,50471 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$39$46,26556 claims
NovartisEntresto$106$24,34021 claims
AbbVieSynthroid$620$1,60027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Nags Head

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →